X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs DIVIS LABORATORIES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA DIVIS LABORATORIES GSK PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 59.5 18.1 328.2% View Chart
P/BV x 11.7 3.9 297.4% View Chart
Dividend Yield % 2.1 1.6 133.9%  

Financials

 GSK PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
GSK PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3,8502,484 155.0%   
Low Rs2,966918 323.0%   
Sales per share (Unadj.) Rs332.3142.3 233.6%  
Earnings per share (Unadj.) Rs44.341.9 105.8%  
Cash flow per share (Unadj.) Rs47.246.3 101.9%  
Dividends per share (Unadj.) Rs50.0010.00 500.0%  
Dividend yield (eoy) %1.50.6 249.6%  
Book value per share (Unadj.) Rs202.7161.5 125.5%  
Shares outstanding (eoy) m84.70265.47 31.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.312.0 85.8%   
Avg P/E ratio x76.940.6 189.4%  
P/CF ratio (eoy) x72.236.7 196.6%  
Price / Book Value ratio x16.810.5 159.6%  
Dividend payout %112.923.9 472.7%   
Avg Mkt Cap Rs m288,643451,525 63.9%   
No. of employees `0004.63.7 124.4%   
Total wages/salary Rs m4,4343,649 121.5%   
Avg. sales/employee Rs Th6,104.510,184.4 59.9%   
Avg. wages/employee Rs Th961.6984.1 97.7%   
Avg. net profit/employee Rs Th813.72,998.5 27.1%   
INCOME DATA
Net Sales Rs m28,14837,764 74.5%  
Other income Rs m1,218848 143.6%   
Total revenues Rs m29,36638,612 76.1%   
Gross profit Rs m4,77414,138 33.8%  
Depreciation Rs m2481,182 21.0%   
Interest Rs m023 0.0%   
Profit before tax Rs m5,74413,781 41.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,0182,662 75.8%   
Profit after tax Rs m3,75211,119 33.7%  
Gross profit margin %17.037.4 45.3%  
Effective tax rate %35.119.3 181.8%   
Net profit margin %13.329.4 45.3%  
BALANCE SHEET DATA
Current assets Rs m21,46230,947 69.4%   
Current liabilities Rs m10,5365,195 202.8%   
Net working cap to sales %38.868.2 56.9%  
Current ratio x2.06.0 34.2%  
Inventory Days Days68117 57.9%  
Debtors Days Days1685 19.3%  
Net fixed assets Rs m4,71717,027 27.7%   
Share capital Rs m847531 159.5%   
"Free" reserves Rs m16,30842,341 38.5%   
Net worth Rs m17,17142,877 40.0%   
Long term debt Rs m165 340.4%   
Total assets Rs m30,62049,684 61.6%  
Interest coverage xNM595.0-  
Debt to equity ratio x00 850.0%  
Sales to assets ratio x0.90.8 120.9%   
Return on assets %12.322.4 54.6%  
Return on equity %21.925.9 84.3%  
Return on capital %33.632.2 104.3%  
Exports to sales %085.3 0.0%   
Imports to sales %15.122.9 65.7%   
Exports (fob) Rs m432,198 0.0%   
Imports (cif) Rs m4,2378,654 49.0%   
Fx inflow Rs m51932,270 1.6%   
Fx outflow Rs m8,3208,775 94.8%   
Net fx Rs m-7,80123,496 -33.2%   
CASH FLOW
From Operations Rs m1,38610,379 13.3%  
From Investments Rs m5,010-4,135 -121.2%  
From Financial Activity Rs m-6,383-6,241 102.3%  
Net Cashflow Rs m123 357.6%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.8 86.4%  
FIIs % 23.8 19.0 125.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.2 89.5%  
Shareholders   102,036 31,796 320.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Realty Sector Up 2.7%(11:30 am)

After opening the day higher, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 23, 2017 12:05 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS